Xceleron offers a combination of technology and experimental design you won’t find anywhere else. Throughout the development continuum, Xceleron provides analytical solutions to help you answer questions before they become issues and invaluable foresight to navigate the road ahead. Xceleron’s use of Accelerator Mass Spectrometry (AMS) technology delivers solutions and insight for a range of pharmaceutical challenges. Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.